Primed Microglia is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Primed microglia represent a pre-activated state where microglia have undergone initial sensitization but do not spontaneously release high levels of pro-inflammatory mediators. This intermediate phenotype is characterized by an elevated baseline activation state and enhanced responsiveness to secondary inflammatory challenges. Primed microglia are characterized by:
The concept of microglial priming explains why aging and chronic neurodegenerative conditions predispose the brain to exaggerated neuroinflammatory responses to minor insults [1].
Primed microglia express elevated levels of activation markers compared to resting ( surveilling) microglia:
| Marker | Expression Level | Significance |
|---|---|---|
| MHC-II (HLA-DR) | Moderately elevated | Indicates antigen presentation capability |
| CD68 | Elevated | Phagocytic activity marker |
| CD86 | Moderately elevated | Co-stimulatory molecule |
| C3 | Elevated | Complement component, astrocyte communication |
| TREM2 | Variable | Depends on disease context |
RNA-seq studies reveal primed microglia have distinct gene expression patterns:
Aging is the most common priming factor:
In Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions:
The defining feature of primed microglia is their exaggerated response to secondary stimuli:
A "second hit" or "dual hit" model explains neurodegeneration progression:
This explains why:
Primed microglia respond to secondary challenges with amplified cytokine production:
| Cytokine | Fold Increase (Primed vs. Naive) |
|---|---|
| TNF-α | 10-50x |
| IL-1β | 5-20x |
| IL-6 | 5-15x |
| CXCL8 | 10-30x |
Primed microglia in AD contribute to:
In PD, primed microglia:
Primed microglia in ALS:
In MS:
| Strategy | Approach | Agent/Method |
|---|---|---|
| Repolarization | Shift to M2/neuroprotective | IL-4, IL-10, TGF-β |
| Inflammasome inhibition | Block NLRP3 activation | MCC950 |
| CSF1R inhibition | Reduce microglial numbers | PLX5622 |
| TREM2 activation | Enhance phagocytosis | Anti-TREM2 antibodies |
Understanding microglial priming is crucial for:
The study of Primed Microglia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol. 2014;10(4):217-224. PMID:25451883.
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405. PMID:25792098.
Niraula A, Sheridan JF, Godbout JP. Microglial Priming with Aging and Neuroinflammation. Neuroinflammation. 2017;14(1):158. PMID:28899303.
Chen SH, Oyarzabal EA, Hong JS. Critical role of the innate immune system in the progression of Parkinson's disease. Front Aging Neurosci. 2018;10:306. PMID:30349483.
Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann Transl Med. 2015;3(10):136. PMID:26207229.
Liu J, Borea M, Ballerini C. Microglia: The Emergency Department of the Brain. Neuroscience. 2020;437:144-155. PMID:32445845.
Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med. 2017;23(9):1018-1027. PMID:28886007.